Above: Bayer technician prepares cell culture plates for further tests in a Berlin laboratory/Image Credit: Bayer
Tel Aviv University’s technology transfer company Ramot, announced recently, that it has signed a collaboration agreement with Bayer, a German pharmaceutical multinational, to develop and test new cardiac drugs using 3D printed human heart tissues. The research will be carried out in Laboratory for Tissue Engineering and Regenerative Medicine headed by Professor Tal Dvir.
As a part of this agreement, Tal Dvir’s lab and Bayer will aim to test new cardiology medication for toxicity and efficacy using printed whole human hearts over the next few years.
According to both the parties, The testing on heart tissues ‘could enable faster, cheaper and more efficient screening than Petri dishes’ since drug candidates go through several phases of screening including on human tissue cultures and then on lab animals, before eventually reaching pharmacies.
Professor Dvir explained, “In a Petri dish, all the cells line up in 2D, and it’s only one type of cell. In contrast, our engineered tissues are 3D printed, and therefore better resembles real heart tissues. Our printed tissues contain cardiac muscle, blood vessels and the extracellular matrix which connects the different cells biochemically, mechanically and electrically.
He continued, “Moving away from Petri dishes to 3D printed tissues could significantly improve drug tests, saving precious time and money with the hope of producing safer and more effective medication.”
Dvir continued, “The goal is to offer Bayer the ability to conduct pre-clinical trials on complete printed organs, the Israeli scientist indicated. Our agreement is just the beginning. Our end goal is to engineer whole human hearts, including all the different chambers, valves, arteries and veins – the best analogue of this complex organ – for an even better toxicological screening process.”
Above: World’s first 3D printed heart created from a human tissue completely matches all the anatomical properties of a human patient, using a 3D printer/Image Credit: Getty Images
Ramot CEO Keren Primor Cohen said, “Prof. Dvir’s platform groundbreaking innovation is very promising. We believe that this collaboration with Bayer will support the evaluation and development of new drugs and is a step in building long-term relations with Bayer that we hope will benefit both partners and ultimately patients.”
To further develop the application, Ramot licensed the technology to a spin-off company called Matricelf, which focuses on engineering personalized spinal cord implants to treat paralyzed patients. The company recently secured a large investment, allowing it to reach clinical settings in the near future.
Eckhard von Keutz, Head of Translational Sciences at Bayer “We are excited to start this new collaboration with Tel Aviv University, which will address a new area of early assessment of safety and tolerability of drug candidates,” said Eckhard von Keutz, Head of Translational Sciences at Bayer.
Von Keutz added, “We already have a global network of partners and this new project will enable Bayer to expand its open innovation activities to Israel, which provides a dynamic ecosystem for innovation in biotech and medical research.”
About Manufactur3D Magazine: Manufactur3D is an online magazine on 3D Printing. Visit our Global News page for more updates on 3D Printing Technology News. To stay up-to-date about the latest happenings in the 3D printing world, like us on Facebook or follow us on LinkedIn.
